Enterprise record

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as we

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:f23c27a4-e4f1-438f-af71-bda0a9d5a23fVersion: public-1As of: unavailable

11 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 5 claims
    • Legal Name: Atara Biotherapeutics, Inc. · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 30, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 30, 2026

  2. Atara Biotherapeutics, Inc. DEF 14A 2026-04-24

    sec proxy · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026

    Supports 6 claims
    • Leadership Role: AnhCo Nguyen, Ph.D.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Gregory A. Ciongoli: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: James Huang: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Matthew K. Fust: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Nachi Subramanian: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: William K. Heiden: Director · Claim reviewed: Sep 30, 2026